Clinical Trials Browser

Phase 2 × avapritinib × Myeloid × Clear all

NCT03731260 2025-09-23

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

Phase 2 Active not recruiting

Mastocytosis, Systemic

NCT03580655 2025-04-30

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Phase 2 Completed

107 enrolled 1 FDA

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT05821738 2023-05-09

Avapritinib in CBF-AML With KIT Mutations

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Core Binding Factor Acute Myeloid Leukemia